|
|
HE4及Vimentin在子宫内膜癌中的研究进展
|
Abstract:
子宫内膜癌(Endometrial Cancer, EC)是常见的妇科恶性肿瘤之一，其发病率随着时间的推移而增加，严重威胁妇女的健康与生存。大多数女性以绝经后阴道不规则出血为主要症状。以往，在临床实践中，有症状的妇女通过包括经阴道镜、子宫内膜活检和宫腔镜在内的检查进行诊断。近年来，多项研究证明血清肿瘤标志物以及组织免疫组化标记物在协助EC诊断及监测预后等方面都有重要临床意义。经国内外多项研究证明，血清肿瘤标记物血清人附睾蛋白4 (HE4)水平升高及组织免疫组化标记物波形蛋白(Vimentin, Vim)阳性表达率升高与子宫内膜癌诊断及预后有关。本文旨在讨论术前血清肿瘤标记物HE4联合术后组织免疫组化标记物Vim与子宫内膜癌的分期和病理特征(组织学类型、组织学分级、手术病理分期、肌层浸润深度、淋巴结转移及预后)的相关性，致力于形成可靠的诊疗和预后判断，让妇科医生更好地适应手术分期和辅助治疗，改善子宫内膜癌患者的预后或生活质量。
Endometrial Cancer (EC) is one of the common gynecological malignancies. Its incidence increases with time, which seriously threatens women’s health and survival. In most women, irregular vaginal bleeding after menopause is the main symptom. Historically, in clinical practice, symptomatic women were diagnosed by tests including transcolposcopy, endometrial biopsy, and hysteroscopy. In recent years, a number of studies have demonstrated that serum tumor markers and tissue im-munohistochemical markers have important clinical significance in assisting EC diagnosis and mon-itoring prognosis. A number of studies at home and abroad have proved that the increased level of serum tumor marker human epididymal protein 4 (HE4) and the increased positive expression rate of tissue immunohistochemical marker Vimentin (Vim) are associated with the diagnosis and prog-nosis of endometrial cancer. This paper aims to discuss the correlation between preoperative serum tumor marker HE4 combined with postoperative tissue immunohistochemical marker Vim and the staging and pathological features of endometrial cancer (histological type, histological grade, surgi-cal pathological stage, depth of muscular infiltration, lymph node metastasis and prognosis), so as to form reliable diagnosis, treatment and prognosis, to better adapt gynecologists to surgical staging and adjuvant therapy, improve the prognosis or quality of life of patients with endometrial cancer.
| [1] | O’Toole, S.A., Huang, Y., Norris, L., et al. (2021) HE4 and CA125 as Preoperative Risk Stratifiers for Lymph Node Metastasis in Endometrioid Carcinoma of the Endometrium: A Retrospec-tive Study in a Cohort with Histological Proof of Lymph Node Status. Gynecologic Oncology, 160, 514-519. https://doi.org/10.1016/j.ygyno.2020.11.004 |
| [2] | 王锦, 俞虹, 何建新, 等. 血清和子宫内膜组织CA125和HE4在子宫内膜癌术前评估及不同病理特征中的变化意义[J]. 中国妇幼保健, 2021, 36(11): 2506-2508. |
| [3] | Li, J., Chen, H., Mariani, A., et al. (2013) HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. In-ternational Journal of Molecular Sciences, 14, 6026-6043. https://doi.org/10.3390/ijms14036026 |
| [4] | Cymbaluk-P？oska, A., Gargulińska, P., Bulsa, M., et al. (2021) Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer? Diagnostics, 11, Article No. 626.
https://doi.org/10.3390/diagnostics11040626 |
| [5] | Renner, A.B., Dietrich-Ntoukas, T. and J？gle, H. (2015) Recur-rent Episodes of Night Blindness in a Patient with Short Bowel Syndrome. Documenta Ophthalmologica, 131, 221-230. https://doi.org/10.1007/s10633-015-9516-8 |
| [6] | 龚惠, 金玉华, 何萍, 等. 波形蛋白的表达与子宫内膜癌患者术后预后的关系[J]. 现代生物医学进展, 2017, 17(33): 6460-6464, 6490. |
| [7] | 吕嘉, 宋力雯, 丘瑾, 等. 雌激素受体孕激素受体和波形蛋白在子宫内膜癌的表达及临床意义[J]. 山西医药杂志, 2015, 44(24): 2843-2846. |
| [8] | Liu, C.H., Jiang, Q.P., Lin, D., Chen, W., Xiao, Y.Y., Lin, L., Deng, Y.R., Jiang, H.P. and Guo, S.Q. (2016) Coexpression of MAP2K4 and Vimentin Proteins in Human Endometrial Carcinoma and Its Clinicopatho-logical Significance. Journal of Southern Medical University, 37, 157-164. (In Chinese) |
| [9] | Kidd, M.E., Shumaker, D.K. and Ridge, K.M. (2014) The Role of Vimentin Intermediate Filaments in the Progression of Lung Cancer. American Journal of Respiratory Cell and Molecular Biology, 50, 1-6.
https://doi.org/10.1165/rcmb.2013-0314TR |
| [10] | Domagala, W., Striker, G., Szadowska, A., et al. (1994) P53 Pro-tein and Vimentin M Invasive Ductal Nos Breast Carcinoma—Relationship with Survival and Sites of Metastases. Euro-pean Journal of Cancer, 30, 1527-1534.
https://doi.org/10.1016/0959-8049(94)00288-G |
| [11] | Danielsson, F., Peterson, M.K., Araújo, H.C., Lautenschl？ger, F. and Gad, A.K.B. (2018) Vimentin Diversity in Health and Disease. Cells, 7, Article No. 147. https://doi.org/10.3390/cells7100147 |
| [12] | Mendez, M.G., Kojima, S.-I. and Goldman, R.D. (2010) Vimentin In-duces Changes in Cell Shape, Motility, and Adhesion During the Epithelial to Mesenchymal Transition. The FASEB Journal, 24, 1838-1851.
https://doi.org/10.1096/fj.09-151639 |
| [13] | Ivaska, J. (2011) Vimentin: Central Hub in EMT Induction? Small GTPases, 2, 51-53.
https://doi.org/10.4161/sgtp.2.1.15114 |
| [14] | Hoffmann, A., Ciani, E., Boeckardt, J., et al. (2003) Transcriptional Activities of the Zinc Finger Protein Zac Are Differentially Controlled by DNA Binding. Molecular and Cellular Biology, 23, 988-1003.
https://doi.org/10.1128/MCB.23.3.988-1003.2003 |
| [15] | 赵静, 刘国雄, 刘宝全. 波形蛋白和Ki-67在宫颈鳞状细胞癌中的表达及其相关性[J]. 山西医药杂志, 2016, 45(1): 17-19. |
| [16] | Zhou, W., Wang, K., Wang, J., et al. (2019) SOX17 Inhibits Tumor Metastasis Via Wnt Signaling in Endometrial Cancer. Oncotargets and Therapy, 12, 8275-8286. https://doi.org/10.2147/OTT.S220536 |
| [17] | Yoriki, K., Mori, T., Kokabu, T., et al. (2019) Estrogen-Related Recep-tor Alpha Induces Epithelial-Mesenchymal Transition through Cancer-Stromal Interactions in Endometrial Cancer. Scien-tific Reports, 9, Article No. 6697.
https://doi.org/10.1038/s41598-019-43261-z |
| [18] | Wik, E., R？der, M.B., Krakstad, C., et al. (2013) Lack of Estro-gen Receptor-α Is Associated with Epithelial-Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma. Clinical Cancer Research, 19, 1094-1105.
https://doi.org/10.1158/1078-0432.CCR-12-3039 |
| [19] | Glubb, D.M., Thompson, D.J., Aben, K.K.H., et al. (2020) Cross-Cancer Genome-Wide Association Study of Endome-trial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Can-cer Epidemiology, Biomarkers & Prevention, 30, 217-228. https://doi.org/10.1158/1055-9965.EPI-20-0739 |
| [20] | Colombo, N., Creutzberg, C., Amant, F., et al. (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Interna-tional Journal of Gynecological Cancer, 26, 2-30.
https://doi.org/10.1097/IGC.0000000000000609 |
| [21] | Njoku, K., Abiola, J., Russell, J. and Crosbie, E.J. (2020) Endometrial Cancer Prevention in High-Risk Women. Best Practice & Research Clinical Obstetrics & Gynaecology, 65, 66-78. https://doi.org/10.1016/j.bpobgyn.2019.12.005 |
| [22] | 邹纯静, 罗庆, 吴谋喜, 等. 血清HE4和CA125预测子宫内膜癌患者不良预后的价值[J]. 中国妇幼保健, 2018, 33(8): 1707-1710. |
| [23] | Paunovic, V., Protrka, Z., Ardalic, D. and Paunovic, T. (2017) Usefulness of Human Epididymis Protein 4 in Predicting Optimal Cytoreductive Therapy in Patients with Advanced Ovarian Cancer. Journal of the Balkan Union of Oncology, 22, 29-33. |
| [24] | Alkushi, A., Irving, J., Hsu, F., et al. (2003) Immunoprofile of Cervical and Endometrial Adenocarcinomas Using a Tissue Mi-croarray. Virchows Archiv, 442, 271-277. https://doi.org/10.1007/s00428-002-0752-4 |
| [25] | Kirchhoff, C., Habben, I., Ivell, R. and Krull, N. (1991) A Major Human Epididymis-Specific cDNA Encodes a Protein with Sequence Homol-ogy to Extracellular Proteinase Inhibitors. Biology of Reproduction, 45, 350-357.
https://doi.org/10.1095/biolreprod45.2.350 |
| [26] | Galgano, M.T., Hampton, G.M. and Frierson, H.F. (2006) Com-prehensive Analysis of HE4 Expression in Normal and Malignant Human Tissues. Modern Pathology, 19, 847-853. https://doi.org/10.1038/modpathol.3800612 |
| [27] | Iwahori, K., Suzuki, H., Kishi, Y., et al. (2012) Serum HE4 as a Diagnostic and Prognostic Marker for Lung Cancer. Tumour Biology, 33, 1141-1149. https://doi.org/10.1007/s13277-012-0356-9 |
| [28] | Wang, X., Fan, Y., Wang, J., Wang, H. and Liu, W. (2014) Eval-uating the Expression and Diagnostic Value of Human Epididymis Protein 4 (HE4) in Small Cell Lung Cancer. Tumour Biology, 35, 6847-6853.
https://doi.org/10.1007/s13277-014-1943-8 |
| [29] | Wojcik, E., Tarapacz, J., Rychlik, U., et al. (2016) Human Epidi-dymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer. Clinical Laboratory, 62, 1625-1632. https://doi.org/10.7754/Clin.Lab.2016.151212 |
| [30] | Lu, M., Ju, S., Shen, X., et al. (2017) Combined Detection of Plasma miR-127-3p and HE4 Improves the Diagnostic Efficacy of Breast Cancer. Cancer Biomarkers, 18, 143-148. https://doi.org/10.3233/CBM-160024 |
| [31] | Dai, H.-Y., Hu, F. and Ding, Y. (2021) Diagnostic Value of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in the Patients with Ovarian Carcinoma: A Protocol for Systematic Review and Meta-Analysis. Medicine, 100, e25981. https://doi.org/10.1097/MD.0000000000025981 |
| [32] | Liu, J., Han, L. and Jiao, Z. (2021) The Diagnostic Value of Human Epididymis Protein 4 for Endometrial Cancer Is Moderate. Scientific Reports, 11, Article No. 575. https://doi.org/10.1038/s41598-020-79960-1 |
| [33] | Moore, R.G., Mcmeekin, D.S., Brown, A.K., et al. (2009) A Novel Multiple Marker Bioassay Utilizing HE4 and CA125 for the Pre-diction of Ovarian Cancer in Patients with a Pelvic Mass. Gynecologic Oncology, 112, 40-46.
https://doi.org/10.1016/j.ygyno.2008.08.031 |
| [34] | Degez, M., Caillon, H., Chauviré-Drouard, A., et al. (2021) En-dometrial Cancer: A Systematic Review of HE4, REM and REM-B. Clinica Chimica Acta, 515, 27-36. https://doi.org/10.1016/j.cca.2020.12.029 |
| [35] | Yilmaz, S.A., Alt？nkaya, S.？., Kerimoglu, ？.S., et al. (2017) The Role of Human Epididymis Secretory Protein E4 in Patients with Endometrial Cancer and Premalignant Endometrial Le-sions. Journal of Obstetrics and Gynaecology, 37, 58-63. https://doi.org/10.3109/01443615.2016.1174199 |
| [36] | 闫跃. 外周血NLR、PLR及血清CA125、HE4与子宫内膜癌转移及分期关系的研究[D]: [硕士学位论文]. 沈阳: 中国医科大学, 2021. |
| [37] | Kalogera, E., Scholler, N., Powless, C., et al. (2012) Correlation of Serum HE4 with Tumor Size and Myometrial Invasion in Endometrial Cancer. Gynecologic Oncology, 124, 270-275. https://doi.org/10.1016/j.ygyno.2011.10.025 |
| [38] | Brennan, D.J., Hackethal, A., Metcalf, A.M., et al. (2014) Serum HE4 as A Prognostic Marker in Endometrial Cancer—A Population Based Study. Gynecologic Oncology, 132, 159-165. https://doi.org/10.1016/j.ygyno.2013.10.036 |
| [39] | Rajadevan, N., McNally, O., Neesham, D., Richards, A. and Naaman, Y. (2021) Prognostic Value of Serum HE4 Level in the Management of Endometrial Cancer: A Pilot Study. Australian and New Zealand Journal of Obstetrics and Gynaecology, 61, 284-289. https://doi.org/10.1111/ajo.13302 |
| [40] | Abbink, K., Zusterzeel, P., Geurts-Moespot, A., et al. (2019) HE4 Is Supe-rior to CA125 in the Detection of Recurrent Disease in the Follow-up of High Risk Endometrial Cancer Patients. Euro-pean Journal of Obstetrics & Gynecology and Reproductive Biology, 234, e117. https://doi.org/10.1016/j.ejogrb.2018.08.415 |
| [41] | Wang, Y., Han, C., Teng, F., Bai, Z., Tian, W. and Xue, F. (2017) Predictive Value of Serum HE4 and CA125 Concentrations for Lymphatic Metastasis of Endometrial Cancer. Interna-tional Journal of Gynecology & Obstetrics, 136, 58-63. https://doi.org/10.1002/ijgo.12010 |
| [42] | Lachej, N., Jonu？ien？, V., Ma？eik？, A., et al. (2019) Changes in the Expression of Notch and Wnt Signalling Molecules in Human Endometrial Cancer. Acta Medica Lituani-ca, 26, 181-190.
https://doi.org/10.6001/actamedica.v26i3.4148 |
| [43] | Ye, L., Wang, X. and Li, B. (2021) Expression Profile of Epi-thelial-Mesenchymal Transition-Related Genes as a Prognostic Biomarker for Endometrial Cancer. Journal of Cancer, 12, 6484-6496. https://doi.org/10.7150/jca.62729 |
| [44] | De Craene, B. and Berx, G. (2013) Regulatory Networks De-fining EMT during Cancer Initiation and Progression. Nature Reviews Cancer, 13, 97-110. https://doi.org/10.1038/nrc3447 |
| [45] | Takai, M., Terai, Y., Kawaguchi, H., et al. (2014) The EMT (Epitheli-al-Mesenchymal-Transition)-Related Protein Expression Indicates the Metastatic Status and Prognosis in Patients with Ovarian Cancer. Journal of Ovarian Research, 7, Article No. 76. https://doi.org/10.1186/1757-2215-7-76 |
| [46] | Zhang, X., Cao, G., Diao, X., et al. (2022) Vimentin Protein in Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma. Disease Markers, 2022, Article ID: 5240046.
https://doi.org/10.1155/2022/5240046 |
| [47] | Papadopoulos, N., Kotini, A., Cheva, A., et al. (2002) Immunohisto-chemical Expression of Vimentin and Secretory Component Antigens in Endometrial Hyperplasia and Neoplasia. Euro-pean Journal of Gynaecological Oncology, 23, 411-414. |
| [48] | G？siorowska, E., Magnowska, M., I？ycka, N., Warcho？, W. and Nowak-Markwitz, E. (2016) The Role of HE4 in Differentiating Benign and Malignant Endometrial Pathology. Ginekologia Polska, 87, 260-264.
https://doi.org/10.17772/gp/62356 |
| [49] | Nesina, I.P., Iurchenko, N.P. and Buchynska, L.G. (2018) Markers of the Epithelial-Mesenchymal Transition in Cells of Endometrial Carcinoma. Experimental Oncology, 40, 218-222.
https://doi.org/10.31768/2312-8852.2018.40(3):218-222 |
